Implantation of anterior segment intraocular nonbiodegradable drug-eluting system
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governs coverage for implantation of anterior segment intraocular non-biodegradable drug-eluting systems (e.g., intracameral travoprost implant) for reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension for Medicare Advantage and Commercial products.
No material clinical or coverage changes in this revision.
Coverage Criteria
Coverage with indication
Covered when the following apply
Per policy, no further medical necessity criteria are listed for coverage.
Benefits not covered or services deemed not medically necessary vary by member contract. Refer to the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to determine whether a specific service is excluded or considered not medically necessary for that member.
This policy does not list explicit conditions that are universally considered not medically necessary. Instead, determinations of noncoverage or lack of medical necessity are made according to the terms of the individual member's contract, Benefit Booklet, Evidence of Coverage, or Subscriber Agreement.
Coding
Provider Actions & Administrative Notes
Prior authorization not required
No prior authorization is required for implantation of an anterior segment intraocular non-biodegradable drug-eluting system; implantation is covered for Medicare Advantage Plans and Commercial Products when medically necessary.
No step therapy requirements specified
The policy notes the device is intended to address poor adherence to topical medications but does not impose any explicit step therapy or prior trial requirements for implantation.
- Background describes use as an alternative for patients with poor adherence to topical medications; no explicit step therapy requirements specified.
Verify member benefits and medical necessity
Verify the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement to confirm whether the implantation procedure and related services are covered and medically necessary under the member's specific contract.
- Confirm applicable benefits and any contract-specific exclusions before scheduling or performing the procedure.
Benefit/coverage variability may trigger denial
Benefits and covered services may vary by group or contract; services not covered or deemed not medically necessary per the member's Benefit Booklet, Evidence of Coverage, or Subscriber Agreement may be denied.
- Check contract-specific coverage to avoid claim denials for non-covered or non‑medically necessary services.
Background
Drug-eluting intracameral implants (for example, the iDose TR® travoprost intracameral implant) are micro‑invasive devices designed to provide sustained intraocular delivery of a prostaglandin analog (travoprost) to lower intraocular pressure in patients with open‑angle glaucoma or ocular hypertension. The implant is anchored through the trabecular meshwork into the sclera and elutes drug over an extended period as an alternative to topical drops, addressing poor patient adherence with multiple daily topical administrations. The iDose TR® device received FDA approval on December 13, 2023 and implantation is indicated per manufacturer labeling to reduce intraocular pressure.
Definitions
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.